NasdaqGS - Nasdaq Real Time Price USD
Bolt Biotherapeutics, Inc. (BOLT)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 4:06 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -0.35 | -0.32 | -1.51 | -1.28 |
| Low Estimate | -0.46 | -0.36 | -1.66 | -2.15 |
| High Estimate | -0.24 | -0.26 | -1.34 | -0.91 |
| Year Ago EPS | -0.43 | -0.47 | -1.83 | -1.51 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | 1.26M | 1.19M | 8.98M | 3.64M |
| Low Estimate | 500k | 400k | 7.4M | -- |
| High Estimate | 2M | 2M | 10.5M | 9.99M |
| Year Ago Sales | 2.53M | 2.09M | 7.88M | 8.98M |
| Sales Growth (year/est) | -50.20% | -43.00% | 14.00% | -59.50% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.5 | -0.48 | -0.51 | -0.48 |
| EPS Actual | -0.43 | -0.47 | -0.28 | -0.56 |
| Difference | 0.07 | 0.01 | 0.23 | -0.08 |
| Surprise % | 14.00% | 2.10% | 45.10% | -16.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.35 | -0.32 | -1.51 | -1.28 |
| 7 Days Ago | -0.35 | -0.32 | -1.51 | -1.28 |
| 30 Days Ago | -0.35 | -0.32 | -1.51 | -1.28 |
| 60 Days Ago | -0.35 | -0.32 | -1.51 | -1.28 |
| 90 Days Ago | -0.3 | -0.27 | -1.34 | -1.07 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BOLT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 18.60% | -- | -- | 3.70% |
| Next Qtr. | 31.90% | -- | -- | 7.90% |
| Current Year | 17.50% | -- | -- | 2.50% |
| Next Year | 15.20% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.88% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Neutral | 8/15/2024 |
| Downgrade | Leerink Partners: Outperform to Market Perform | 5/15/2024 |
| Downgrade | Jones Trading: Buy to Hold | 5/15/2024 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 5/15/2024 |
| Downgrade | Guggenheim: Buy to Neutral | 5/15/2024 |
| Downgrade | Stifel: Buy to Hold | 5/15/2024 |
Related Tickers
SEER Seer, Inc.
1.9300
-0.52%
TBPH Theravance Biopharma, Inc.
8.80
+2.09%
PMVP PMV Pharmaceuticals, Inc.
1.5800
-1.25%
GLTO Galecto, Inc.
7.12
+5.79%
HLVX HilleVax, Inc.
1.8800
+0.53%
ACHL Achilles Therapeutics plc
1.0000
+1.01%
ANTX AN2 Therapeutics, Inc.
1.0500
+1.94%
SNSE Sensei Biotherapeutics, Inc.
0.4131
-5.25%
OKUR OnKure Therapeutics, Inc.
18.51
+3.12%
SPRO Spero Therapeutics, Inc.
1.2800
-0.39%